ReNeuron Group plc Stock price

Equities

RENE

GB00BF5G6K95

Biotechnology & Medical Research

Market Closed - London S.E. 09:30:01 2024-02-05 am EST 5-day change 1st Jan Change
3.375 GBX -2.17% Intraday chart for ReNeuron Group plc -.--% -3.57%
Sales 2022 403K 509K Sales 2023 530K 669K Capitalization 5.17M 6.53M
Net income 2022 -9M -11.36M Net income 2023 -5M -6.31M EV / Sales 2022 8.48 x
Net cash position 2022 13.99M 17.66M Net cash position 2023 6.73M 8.5M EV / Sales 2023 -2.94 x
P/E ratio 2022
-1.79 x
P/E ratio 2023
-0.96 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 79.3%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.17%
3 months-3.57%
6 months-42.31%
Current year-3.57%
More quotes
Current year
3.28
Extreme 3.275
5.80
1 year
3.28
Extreme 3.275
10.80
3 years
3.28
Extreme 3.275
153.78
5 years
3.28
Extreme 3.275
335.00
10 years
3.28
Extreme 3.275
650.00
More quotes
Managers TitleAgeSince
Director of Finance/CFO 58 14-09-30
Chief Operating Officer - 16-12-31
Chief Tech/Sci/R&D Officer - 22-03-02
Members of the board TitleAgeSince
Director/Board Member 61 22-03-21
Chairman 71 21-06-30
Director/Board Member 61 21-07-13
More insiders
ReNeuron Group plc is a United Kingdom-based Stem Cell and Exosome Technologies company that utilizes its stem cell technologies to develop treatments for disease with unmet needs. The Company has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities. The Company's CustomEX platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. The Company offers a delivery mechanism for a variety of payloads such as small interfering Ribonucleic Acid (siRNA), messenger RNA (mRNA), proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company has the ability to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
More about the company

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock ReNeuron Group plc - London S.E.